Press Release Archive
-
Ibrutinib Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Data Published in The New England Journal of MedicineA second study in relapsed/refractory mantle cell lymphoma (MCL) also published in the online edition
-
Ibrutinib Data Published in The New England Journal of Medicine Show 68 Percent Overall Response Rate in Patients with Relapsed/Refractory Mantle Cell Lymphoma (MCL)A second study in relapsed/refractory chronic lymphocytic leukemia (CLL) also published in the online edition
-
Latest Data for Type 2 Diabetes Treatment INVOKANA™ (canagliflozin) to be Presented at American Diabetes Association Annual MeetingLate-Breaking Phase 3 Results and Health Economics Data are Among 17 Accepted Presentations
-
World Health Organization Issues Interim Guidance on Bedaquiline
-
Johnson & Johnson Announces Definitive Agreement To Acquire Aragon Pharmaceuticals, Inc.
-
Mentor Receives FDA Approval For MENTOR® MEMORYSHAPE™ Breast Implants
-
Updated Results of Two Phase 2 ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma
-
New 1-Day ACUVUE® TruEye® Brand Contact Lenses (narafilcon A) Now Available In U.S.U.S. Upgraded to Global Standard of Popular Daily Disposable Brand
-
Codman Neuro Obtains CE Mark For Enhanced REVIVE SE™ Thrombectomy DeviceSelf-Expanding Clot Removal Device for Ischemic Stroke Features Newly Enhanced Navigation
-
STELARA® Phase 3 Study Published In The Lancet Reports One Year Efficacy And Safety In Treatment Of Active Psoriatic ArthritisData Show Interleukin-12/23 Inhibitor STELARA Improved Joint, Soft Tissue and Skin Components of Psoriatic Arthritis